NRAS and melanoma: By contrast, high-CSD melanomas do not harbor BRAF V600E mutations but present other mitogen-activated protein kinase (MAPK) pathway mutations, such as BRAF V600K, NRAS G12/G13, or KIT mutations, or inactivation of the negative regulators of Ras, such as NF1 or RASA2.